A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis
A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis
复制标题
DOI：
10.1056/nejmoa043876
复制
发表时间：
2005-06-09
影响因子：
158.5
通讯作者：
Boon, NA
中科院分区：
文献类型：
--
作者：
Cowell, SJ;Newby, DE;Boon, NA
背景：钙化性主动脉瓣狭窄与动脉粥样硬化有许多共同特征，包括高胆固醇血症。我们假设强化降脂治疗可以阻止钙化性主动脉狭窄的进展或诱导其消退。方法：在这项双盲、安慰剂对照试验中，钙化主动脉瓣狭窄患者被随机分配每天接受80mg阿托伐他汀或匹配的安慰剂。分别采用多普勒超声心动图和螺旋计算机断层扫描评估主动脉瓣狭窄和钙化。主要终点为主动脉血流速度和主动脉瓣钙评分的变化。结果：77名患者被分配到阿托伐他汀组，78名患者被分配到安慰剂组，中位随访时间为25个月（范围7至36）。安慰剂组血清低密度脂蛋白胆固醇浓度维持在130+/-30 mg /分升，阿托伐他汀组降至63+/-23 mg /分升(P
BACKGROUND:Calcific aortic stenosis has many characteristics in common with atherosclerosis, including hypercholesterolemia. We hypothesized that intensive lipid-lowering therapy would halt the progression of calcific aortic stenosis or induce its regression.METHODS:In this double-blind, placebo-controlled trial, patients with calcific aortic stenosis were randomly assigned to receive either 80 mg of atorvastatin daily or a matched placebo. Aortic-valve stenosis and calcification were assessed with the use of Doppler echocardiography and helical computed tomography, respectively. The primary end points were change in aortic-jet velocity and aortic-valve calcium score.RESULTS:Seventy-seven patients were assigned to atorvastatin and 78 to placebo, with a median follow-up of 25 months (range, 7 to 36). Serum low-density lipoprotein cholesterol concentrations remained at 130+/-30 mg per deciliter in the placebo group and fell to 63+/-23 mg per deciliter in the atorvastatin group (P